Clinical Infectious Diseases Review Time

CID's official pages now do two things unusually well. First, the author guidance says the journal aims to make desk rejection decisions within one week of submission. Second, the "Why Publish" page shows medians both with and without desk rejects included.

That distinction matters a lot. It tells you the journal is not hiding the ball. The better planning model is:

• expect a fast answer if the paper is not clinically right for CID
• expect roughly five to six weeks to first decision if the paper enters full review
• expect about two to two-and-a-half months to final decision on reviewed manuscripts

The official split is much more useful than anecdotal forum posts.

Source: OUP Clinical Infectious Diseases publisher journal metrics + SciRev community data + OUP author guidelines (academic.oup.com portal); ranges reflect typical bands rather than worst-case outliers.

That is the cleanest way to think about CID. It is not a universally fast journal. It is a journal with a very efficient front-end filter.

CID has a sharp clinical identity. It wants studies that change diagnosis, treatment, prevention, or patient management. That makes early filtering easier than at many journals.

Editors can reject quickly when a manuscript is:

• largely microbiology without patient outcomes
• underpowered for its stated clinical endpoint
• describing an interesting pathogen or resistance mechanism without bedside consequence
• clinically relevant only in a very narrow local way
• using observational data to make stronger treatment claims than the design supports

The one-week desk target and the 6-day first-decision median are both easy to understand once that editorial filter is clear.

The slower papers are usually not obviously wrong for the journal. They are the ones where the clinical message is plausible but still contestable.

The common causes are:

• reviewer disagreement about whether the result really changes practice
• cohort size or follow-up questions that weaken confidence in the main endpoint
• studies that bridge clinical infectious disease and microbiology awkwardly
• revision requests around generalizability, stewardship implications, or causal overreach
• outbreak or epidemiology papers whose immediate relevance is less obvious outside one setting

When CID feels slow, it is often because the editors and reviewers are testing whether the study earns the phrase "clinically useful" rather than merely sounding clinically adjacent.

For year-over-year citation data, see the Clinical Infectious Diseases citation metrics page.

Clinical Infectious Diseases is down from 11.8 in 2023 to 7.3 in 2024, which is best read as post-pandemic normalization rather than editorial decline. The 5-year JIF of 7.2 and the journal's still-large citation footprint suggest a stable post-spike baseline.

For review time, that stability helps explain why the journal can keep triaging hard. CID does not need to widen its scope to preserve relevance. It can keep deciding quickly whether the paper will matter to practicing infectious disease readers.

Even with this unusually good official dashboard, a few things stay hidden:

• desk rejections dramatically compress the all-submission medians
• a paper can reach first decision in 39 days and still face a major revision
• the "without desk rejects" number still masks big differences by article type
• timing does not tell you whether the paper is too descriptive, too local, or too weakly practice-facing

So the numbers are excellent planning tools, but they are not substitutes for scope discipline.

In our pre-submission review work, the biggest timing mistake is sending a paper that is clinically adjacent rather than clinically decisive. CID editors usually identify that immediately.

The files that move most cleanly through CID tend to have:

• patient outcomes or clinical management consequence visible in the abstract
• a cohort large enough for the claimed endpoint
• conclusions disciplined to the limits of the design
• clear relevance to diagnosis, treatment, prevention, stewardship, or management

Those are the traits that use CID's fast front end well. Otherwise the speed mostly becomes a fast rejection signal.

In our pre-submission review work on CID-targeted manuscripts, three patterns most consistently predict slow review at Clinical Infectious Diseases (Oxford University Press). Of manuscripts we screened in 2025 targeting CID and peer venues, the patterns below are the same ones our reviewers flag in real time. The named editorial-culture quirk: CID editors enforce practice-changing-evidence threshold; mechanism-only papers without immediate clinical-translation pathway extend revision.

Scope-fit ambiguity in the abstract. CID editors move fastest on manuscripts whose contribution is obviously aligned with the journal's editorial scope (practice-changing infectious-disease research). The named failure pattern: mechanism-only infectious-disease papers without clinical-translation pathway extend revision rounds. Check whether your abstract reads to CID's scope →

Methods package incomplete for the journal's reviewer pool. CID reviewers expect specific methodological detail. Observational studies without explicit confounding-adjustment strategy extend reviewer assignment. Check if your methods package is reviewer-complete →

Reference-list and clean-citation failure mode. Editorial team at Clinical Infectious Diseases (Oxford University Press) screens reference lists for retracted-paper inclusion. Check whether your reference list is clean against Crossref + Retraction Watch →

Editorial detail (for desk-screen calibration). Verify the current Editor-in-Chief and handling-editor list on the journal's editorial-team page before quoting any name in a submission cover letter. Submission portal: https://mc.manuscriptcentral.com/cid. Manuscript constraints: 250-word abstract limit and 3,500-word main-text cap (CID enforces during desk-screen). We reviewed each of these constraints against current journal author guidelines (accessed 2026-05-08); evidence basis for the patterns above includes both publicly documented author-guidelines and our internal anonymized submission corpus.

Manusights submission-corpus signal for Clinical Infectious Diseases (Oxford University Press). Of the manuscripts our team screened before submission to CID and peer venues in 2025, the editorial-culture mismatch most consistent across the cohort is Cid editors enforce practice-changing-evidence threshold; mechanism-only papers without immediate clinical-translation pathway extend revision. In our analysis of anonymized CID-targeted submissions, the documented review timeline shows a bimodal distribution between manuscripts that clear CID's scope-fit threshold within the first week and those that get extended editorial-board consultation. Top-line triage is handled by the journal's editorial team; verify the current handling editor on the journal's editorial-team page before quoting any name in a cover letter.

For CID, timing matters less than clinical utility. The better question is whether the manuscript already behaves like a Clinical Infectious Diseases paper.

That is why the better next reads are:

• Clinical Infectious Diseases journal profile
• Clinical Infectious Diseases submission guide
• Clinical Infectious Diseases citation metrics
• Clinical Infectious Diseases acceptance rate

A CID clinical-utility check is usually higher leverage than trying to optimize around review speed alone.

Clinical Infectious Diseases review time is a strong example of why journals should separate desk-reject medians from reviewed-paper medians. CID does, and the result is actually useful. The journal is fast to decide whether the paper belongs, then more normally paced once the paper earns peer review.

The Manusights CID readiness scan. This guide tells you what Clinical Infectious Diseases (Oxford University Press)'s editors look for in the first 1-2 weeks of triage. The review tells you whether YOUR paper passes that check before you submit. We have reviewed manuscripts targeting Clinical Infectious Diseases (Oxford University Press) and peer venues; the named patterns below are the same ones the journal's handling editors and outside reviewers flag at the desk-screen and first-review stages. documented review timeline of approximately 7-10 days for desk-screen. 60-day money-back guarantee. We do not train AI on your manuscript and delete it within 24 hours.